Setmalanotide Phase 2 Trial In Patients With Rare Genetic Disorders Of Obesity (H-43952)
Study Goal(s): To determine the effect of setmelanotide (RM-493) on weight, hunger assessments and other factors in patients with rare genetic disorders of obesity.
Eligibility Criteria: (at BCM/TCH) ages 6-18 yo with a genetic form of obesity including Smith-Magenis, 16p11.2 deletion syndrome, MC4R, leptin deficiency with loss of response to metreleptin, CPE deficiency, or POMC/PCSK1/LEPR deficiency
Investigators: Stephanie Sisley, M.D. (site principal investigator)
Supported by: Rhythm Pharmaceutics